Profil Institute for Clinical Research, an clinical research organization (CRO) focused on diabetes, obesity and NAFLD/NASH, announced today a strategic collaboration with Gubra ApS, a metabolic preclinical and drug discovery company, to combine expertise and resources to discover and translate into clinical research novel drug targets, compounds and biomarkers addressing metabolic disease.
According to the terms of the collaboration, Gubra will provide metabolic drug discovery expertise and pre-clinical target validation, as well as preclinical services, including in vivo pharmacology, histology and stereology, molecular biology, and assay development. Profil Institute will provide early phase clinical services, regulatory management, and execution of clinical studies based on compound specific target product profiling and clinical development planning.
Both companies are members of the Profil Institute founded Metabolic Research Partners™ network, an alliance of science and quality driven metabolism focused services providers to the biopharmaceutical and venture capital industries.
"We are delighted at the prospect of working with Profil Institute, bringing together their clinical development and regulatory planning expertise with Gubra´s preclinical skills and know-how", said Dr. Niels Vrang, Gubra CEO. "Not only is the complementarity between our companies nearly perfect, but we also find that the physical bridging of US and Europe biotech companies in collaborations like this has the potential to unlock ideas and opportunities that either company could not do by themselves. Additionally, for Gubra this collaboration not only consolidates the development of our early drug discovery candidates, but has the potential to boost our current target discovery programs in CNS obesity and NASH/NAFLD."
"Gubra and Profil Institute are two leading science driven organizations, solely focused on metabolism, addressing adjacent stages of the drug development process. Individually, the two companies have unrivaled expertise and experience in their specific stages of metabolic research and development," said Dr. Marcus Hompesch, Profil Institute CEO. "Together, we will contribute to highly efficient and effective metabolic drug development through meaningful science, advanced methodologies, and a combined team of experts."
Research explores the health benefits of resistant starch in plant-based diets